F. Finley. Knox College.
Figures comparing individual drug concentration-time profiles of the two products drawn on a linear/linear scale buy 0.625mg premarin mastercard menopause systems. Figures comparing average drug level-time profiles of the two products drawn on a linear/linear scale buy premarin 0.625mg line women's health center gainesville fl. Analysis of pharmacokinetic parameters If deconvolution is used discount premarin 0.625mg line breast cancer apparel, the program, algorithm, pharmacokinetic models and fitting information should be listed. Others Information on dropouts (data, reasons), monitoring records of health status of subjects. Among the three lots, the one which shows intermediate dissolution should be selected as the reference product. When the average dissolution of any of the lots does not reach 85%, the test solution providing the fastest dissolution should be used. If a reference product cannot be appropriately selected for the drug product by dissolution testing as described above, the reference product should be the innovator product lot that shows intermediate characteristics when either a dissolution (release) test appropriate for the characteristics of the drug product or a substitute physicochemical test is performed. The test generic product must not differ markedly from the innovator product in size, shape, specific gravity or release mechanism. The dissolution behaviour of the test product must be similar to that of the reference product. Test Method Bioequivalence studies should be performed by single dose studies in both the fasted and fed states. In the case of postprandial administration, a high fat diet of 900 kcal or more containing 35% lipid content should be used. The meal should be eaten within 20 min, and drugs administered within 10 min thereafter. When a high incidence of severe adverse events is indicated after dosing in the fasting state, the fasting dose studies can be replaced with postprandial dose studies with the low fat meal employed in the study for oral immediate release products and enteric-coated products. Other testing conditions should follow those of oral immediate release products and enteric-coated products. Assessment of bioequivalence 1) Bioequivalence range, parameters, data transformation and statistical analysis These are the same as those of oral immediate release products and enteric-coated products. The assessment of reference parameters follows that of oral immediate release products and enteric-coated products. Pharmacodynamic and clinical studies If bioequivalence studies cannot be performed, pharmacodynamic or clinical studies should be carried out to evaluate therapeutic equivalence according to the studies for oral immediate release products and enteric-coated products. The test can be stopped at the time when the average dissolution of reference product reaches 85%. Apparatus: Paddle apparatus, rotating basket and disintegration testing apparatus can be selected, the reason for which should be stated. Volume of test solution, Temperature and Test solutions should follow the description of oral immediate release products and enteric-coated products. When the average dissolution of the reference product does not reach 80 % within 24 hr in any of test fluids, the test solution where the dissolution is the fastest should be selected. Acceptance criteria for similarity and equivalence of dissolution profiles If the results meet one of the following criteria shown in 1) under all testing conditions, the dissolution profile of the test product is judged to be similar to that of the reference product. If the average dissolution of the reference product reaches 80% within the testing time point specified in at least one test condition, and the results meet one of the following criteria shown in 2) under all testing conditions, the dissolution profile of the test product is judged to be equivalent to that of the reference product. When similarity factor, f2, is used, Appendix 1 (2) Time points for f2 should be employed. A judgement of similarity or equivalence in dissolution does not mean bioequivalence. When the average dissolution of the reference product reaches 80% within the testing time specified: the average dissolution of the test product are within that of the reference product ± 15% at three appropriate time points when the average dissolution of the reference product are around 30%, 50% and 80%. When the average dissolution of the reference product reaches 50% and does not reach 80% within the testing time point specified: the average dissolution of the test product are within that of the reference product ± 12% at the testing time specified and at an appropriate time point when the average dissolution of the reference product reaches about a half of the average dissolution at the testing time specified. When the average dissolution of the reference product does not reach 50% within the testing time specified: the average dissolution of the test product are within that of the reference product ± 9% at the testing time specified and at an appropriate time point when the average dissolution of the reference product is about a half of the average dissolution at the testing time specified. However, when the average dissolution of the reference product is not more than 10% within the testing time specified, the average dissolution of the test product is within that of the reference product ± 9% at the testing time specified only. When the average dissolution of the reference product reaches 80% within the testing time specified: the average dissolution of the test product are within that of the reference product ± 10% at three appropriate time points when the average dissolution of the reference product are around 30%, 50% and 80%. When the average dissolution of the reference product reaches 50% and does not reach 80% within the testing time point specified: the average dissolution of the test product are within that of the reference product ± 8% at the testing time specified and at an appropriate time point when the average dissolution of the reference product reaches about a half of the average dissolution at the testing time specified. When the average dissolution of the reference product does not reach 50% within the testing time specified: the average dissolution of the test product are within that of the reference product ± 6% at the testing time specified and at an appropriate time point when the average dissolution of the reference product is about a half of the average dissolution at the testing time specified. However, when the average dissolution of the reference product is not more than 10% within the testing time specified, the average dissolution of the test product is within that of the reference product ± 6% at the testing time specified only. Reporting of test results The shape, specific gravity and release mechanism of the test product should be described which do not differ significantly from those of the innovator product. The description of other results is the same as that for oral immediate products and enteric-coated products (Sec. Non-oral dosage forms The test for the products for topical use should be following the Guideline for Bioequivalence Studies of Generic Products for Topical Use an attachment of Division-Notification No. For other non-oral dosage forms, the test should be performed following the description below. Reference and test products Suitable release tests or alternative physicochemical tests should be performed for three lots of an innovator product from which one lot providing intermediate characteristics should be selected as a reference product. If the drug is administered as a liquid where the active ingredient dissolves, an appropriate lot can be used as a reference product. The lot size and drug content or potency follows the description for oral immediate release products and enteric-coated products. Bioequivalence studies The test should follow the bioequivalence test for oral immediate release products and enteric-coated products but the results of release or physicochemical tests are not used as supportive data for the assessment of bioequivalence. Pharmacodynamic and clinical studies Follow the description of the oral immediate release products and enteric-coated products. Appropriate animal studies will be allowed for products for topical use (skin, etc. For bactericides for external use, appropriate in vitro efficacy tests can be employed. Dissolution (release) tests or physicochemical tests Release or physicochemical characteristics should be compared between test and reference products by appropriate tests which will vary depending on the product. Reporting of test results Follow the description of the oral immediate release products and enteric-coated products. Dosage forms of which bioequivalence studies are waived Injections for intravenous administration, administered as an aqueous solution. Ti and Ri show the average dissolutions of the test and reference products at the time point (i), respectively, and n is the number of time points at which the average dissolution are compared. Adjusting dissolution curves with lag times The lag time is defined as the time when 5% of the labeled claim of the active ingredient dissolves from the product. A lag time should be determined for respective product by linear interpolation, and then respective dissolution curve is obtained by 22 adjusting dissolution curve with the lag time. Average dissolution curves of the test and reference products are obtained, which can be used for the assessment of similarity and equivalence in dissolution curves. R eference product Testproduct 4)Ifth ereisgeneticpolymorph ism,subjectswith h igh erclearancesh ouldbeemployed.
I acknowledge Sasu Siikamäki for the cover design and assistance with the graphical layout of this thesis premarin 0.625mg low cost pregnancy ecards. I feel great gratitude to my mother Liisa and father Heikki for their love and support throughout my life purchase cheapest premarin and premarin women's health magazine birth control pills. My sisters Maarit and Pauliina and their husbands Panu and Yrjö are thanked for their help and support discount premarin online master card menstruation cycle calculator. My parents-in-law Tarja and Markus also deserve warm thanks for their interest in my work. My brother-in-law Esa and his wife Anniina are thanked for sharing these years with me. Finally, my deepest and the most sincere thanks go to my dearly beloved wife Mirja for her support and understanding during these years and for taking care of our wonderful son Rasmus, who has filled my life with happiness. In the published version of abstract (results) the number of operations should be “3. A corrected version of the table is displayed below: The patients underwent an average of 3. The unit in the legend should be “months” instead of “years” in the published version of Figure 4. We ensure there is solid involving over 100 companies who are major generators of carbon dioxide in Ireland. Wexford, Ireland Telephone: + 353 53 9160600 Fax: + 353 53 9160699 Email: info@epa. Neither the Environmental Protection Agency nor the author(s) accept any responsibility whatsoever for loss or damage occasioned or claimed to have been occasioned, in part or in full, as a consequence of any person acting or refraining from acting, as a result of a matter contained in this publication. All or part of this publication may be reproduced without further permission provided the source is acknowledged. John Fitzgerald, Inspector, Department of Environment, Community and Local Government Mr. Peter O’Reilly, Senior Engineer, Fingal County Council (representing the Water Services Training Group) Mr. The Environmental Protection Agency was established in 1993 to licence, regulate and control activities for the purposes of environmental protection. In the Environmental Protection Agency Act, 1992 (Section 60), it is stated that “the Agency may, and shall if so directed by the Minister, specify and publish criteria and procedures, which in the opinion of the Agency are reasonable and desirable for the purposes of environmental protection, in relation to the management, maintenance, supervision, operation or use of all or specified classes or plant, sewers or drainage pipes vested in or controlled or used by a sanitary authority for the treatment of drinking water…. This manual has been prepared to reflect best practice in drinking water disinfection. Daily log sheets for operators of disinfection equipment for the verification of disinfection system operation. Source waters, susceptible to surface contamination, particularly surface waters and groundwater and spring sources contain micro-organisms such as bacteria, viruses and protozoan parasites (e. Cryptosporidium) which can present a risk to human health if not effectively treated and disinfected. The overriding objective of water treatment is the removal or inactivation of pathogenic micro-organisms to prevent the spread of waterborne disease. It is important that water treatment works be equipped with adequate disinfection systems, when pristine water supplies collected from catchments totally under the control of the water supply authority are now a rarity. Removal of pathogenic organisms is effected by processes involving addition of coagulant chemicals followed by sedimentation and filtration and by other filtration processes such as membrane filtration. In contrast to removal, the concept of inactivation of pathogens in water relates to the effect that the application of a disinfectant has in destroying the cellular structure of the micro-organisms or in disrupting its metabolism, biosynthesis or ability to grow/reproduce. In the case of bacteria, inactivation describes the subsequent inability of the microorganism to divide and form colonies. For viruses, inactivation measures the inability of the microorganism to form plaques in host cells. For protozoan Cryptosporidium oocysts, it measures the inability of the microorganism to multiply, thereby preventing consequent infection of a host by Cryptosporidium. The philosophy underlying disinfection of all water supplies is to use the best quality source of water available and to provide multiple barriers to the transmission of any pathogenic organisms to consumers. Objective of the updated manual The objective of this disinfection manual is to provide practical guidance and information to the following: a) Water Service Authorities and Private Water Suppliers to allow them to design and operate water treatment systems to provide rigorous disinfection, whilst maintaining compliance with other water quality parameters, particularly in relation to disinfection by-products. This Guidance Manual does not deal with the hazards posed by the generation, storage or use of these chemicals in water treatment or disinfection, the interaction of these chemicals or the associated risks for plant operators Water Treatment Manual: Disinfection managing the production of drinking water for Water Service Authorities or private drinking water suppliers. The Safety, Health and Welfare Act 2005 addresses the responsibilities of Water Service Authorities and private suppliers in the management of these operator risks. Regulation 5 stipulates that “measurement of compliance with the parametric values specified in Part 1 of the Schedule shall be made in the case of— (a) water supplied from a distribution network or a private source, at the point within a premises at which it emerges from the tap or taps that are normally used for the provision of water for human consumption; (b) water supplied by tanker or similar means, at the point at which it emerges from it; (c) water used in a food-production undertaking, at the point where the water is used in the undertaking. Regulation 4 directs that “Water shall be regarded as wholesome and clean if - (a) it is free from any micro-organisms and parasites and from any substances which in numbers or concentrations, constitute a potential danger to human health, and (b) it meets the quality standards specified …. Regulation 7 (10) stipulates that the Supervisory Authority shall ensure “additional monitoring is carried out on a case-by-case basis (whether by itself or the relevant water supplier) of substances and micro-organisms for which no parametric value has been specified in Part 1 of the Schedule, if there is reason to suspect that such substances or micro-organisms may be present in amounts or numbers that constitute a potential danger to human health” Water Treatment Manual: Disinfection and may issue direction to a supplier where it is of the “opinion that— (a) non-compliance with a water quality standard or other parametric value specified in Part 1 of the Schedule, or (b) the presence of any substance or micro-organism for which no water quality standard has been prescribed, in water intended for human consumption, or the inefficiency of related disinfection treatment, constitutes, or may constitute, a risk to human health” C. Regulation 9 requires that if Water Service Authorities “… in consultation with the Health Service Executive, considers that a supply of water intended for human consumption constitutes a potential danger to human health, the authority shall…. Regulation 13 sets out as follows the obligations of Water Service Authorities and regulated Private Water Suppliers with respect to the monitoring and verification of disinfection systems; “where disinfection forms part of the preparation or distribution of water intended for human consumption, the efficiency of the disinfection treatment is verified and that any contamination from disinfection by-products is kept as low as possible without compromising the disinfection, in accordance with such directions as the relevant supervisory authority may give”. However many of these disinfectant chemicals if overdosed or used inappropriately, as part of a water treatment process, can result in the formation of disinfection by-products. Disinfection by-products are formed when disinfection chemicals react with organic or inorganic compounds. Research shows that human exposure to these by- products may have adverse health effects. The most common chemical disinfectant for water treatment, and the one that has historically made the greatest contribution to the prevention of waterborne disease worldwide, is chlorine. Chlorine for water treatment is generally obtained and used as either liquefied chlorine gas or as sodium hypochlorite solution. Water Treatment Manual: Disinfection Regulatory implications for the use of chlorine relate primarily to by-products. Chlorine is used not only as a primary disinfectant in water treatment, but is also added to provide a disinfectant residual to preserve the water in distribution, where the chlorine is in contact with the water for much longer than during treatment. In many situations, this is the more significant factor in terms of organochlorine by-product formation, and is a driver in the implementation of chloramination in other countries. In chloramination, chlorine is normally added first as the primary disinfectant for treatment, followed by ammonia after the chlorine contact tank to form monochloramine prior to distribution. Ozone is a very effective disinfectant, and where it is used for other purposes, usually for removal of organic micropollutants such as pesticides, it provides benefits in terms of reducing the microbiological challenge to downstream disinfection. Chlorine dioxide is used as a primary disinfectant and in distribution worldwide, but there are limitations to its use because of the inorganic by-products chlorite and to a lesser extent chlorate. Many of these disinfectants are also employed as oxidation agents to improve the efficiency of coagulation/filtration, reduce iron and manganese, remove taste and odour and control algal growth. The possible cumulative effect of these oxidants on by-product formation in combination with their use for disinfection purposes also needs to be understood and risk assessed. Its implementation is increasing worldwide, partly to reduce the amount of chlorine used and minimise the potential for by-product formation, but also because of recent recognition that it provides effective inactivation of Cryptosporidium and other pathogenic protozoa. This monitoring is done on drinking water entering supply and at certain fixed and random locations within the distribution system.
Each (ipatropium) works in about 15 minutes and lasts for 6–8 bronchodilator is different cheapest generic premarin uk menstrual reg, based on 1 buy premarin amex menopause 2 periods in a month. Your health forms take about 20 minutes to begin working and last 24 care provider will work with you to decide which of these hours (tiotropium buy generic premarin 0.625mg on line menopause 33, umedclidinum) or 12 hours (aclidinium) medications or combinations work best for you. Because of the slower onset of action of anticholinergics, they are not to be used for quick relief (reliever medicine). Types of bronchodilators: beta2-agonists Common side effects when taking anticholinergics anticholinergics Anticholinergic bronchodilators do not have as many side theophyllines effects as beta2-agonists. The most common side effects are Beta -Agonists dry mouth and diffculty passing urine (urinary retention). Short- Understanding why you are taking two different lasting beta2-agonists (albuterol, pirbuterol, salbutamol, bronchodilators may be confusing. You may be given a beta2- terbutaline) last for 4-6 hours, while long-lasting (salmeterol, agonist with an anticholinergic because the two work better formoterol) can last for up to 12 hours. Albuterol and terbutaline are a fast-acting bronchodilator with a long-lasting bronchidilator. Using your reliever medication before an activity that you When taking theophylline, a blood test must be done to know makes your breathing worse (exercise, showering, or check your theophylline level. The amount of theophylline going out into the cold air) may help lessen or prevent your you take needs careful supervision since your theophylline breathing diffculty. If you experience Common side effects when taking beta2-agonists any of these, get medical care immediately. Often this combination of fast heartbeat and shakiness Steroids, also known as corticosteroids, are medications used can cause anxiety and worsen breathlessness. These side effects can last for not the same as anabolic steroids (misused by athletes) to a few minutes after taking the medicine, and may totally go build muscles. The inhaled away, talk to your health care provider, who may stop or reduce steroid may be combined with a bronchodilator. They do not work quickly, however, and may take and spacer/chamber to your clinic visit and review your a week or more before you notice the benefts. Pills can act medicines and the way you use them with your health care faster (within 24 hours) than inhaled steroids, but can cause provider. Examples of bronchodilator actions and common Common side effects when taking steroid medications side effects: Side effects depend on the dose, length of use, and whether Beta -agonist Anticholinergic Theophylline 2 taken by pill or inhaled. The most common side effects of Short-lasting albuterol, pirbuterol, ipatropium ✔ inhaled steroids are a sore mouth, hoarse voice, and infections (4-6 hours) salbutamol, terbutaline in the throat and mouth. You can avoid or reduce these side Long-lasting Indacaterol, formoterol, aclidinium, ✔ effects by rinsing your mouth after taking an inhaled steroid. Fast-acting albuterol, formoterol, Taking steroids by pill in high doses, or taking low doses (5 minutes) salbutamol, terbutaline for a long time, may cause problems including bruising Slow-acting salmeterol ipatropium, ✔ of the skin, weight gain, weakening of the skin and bones (20 minutes or more) tiotropium (osteoporosis), cataracts, increased blood sugar, mood Side Effects: changes, muscle weakness, and swelling of the ankles or feet. Shakiness ✔ ✔ Patients who use inhaled steroids may have a higher risk of ✔ Dry mouth pneumonia. While many of these unwanted effects can be Fast heart rate ✔ ✔ troublesome, not taking steroids when they are needed can lead to severe, life-threatening breathing problems. You should Nausea/ ✔ Stomach upset discuss any concerns about taking steroids with your health Muscle Cramps ✔ ✔ care provider. For people with frequent American Thoracic Society exacerbations despite being on bronchodilators and steroids, http://patients. Rofumilast is a new medication that may decrease the number of exacerbations Canadian Lung Association you have. Both can have side effects so it is important to discuss the risks and benefts with your health care provider. The brand name is decided by the maker (or makers) of the ✔ Review how you take your medicines with your health medicine. Brand names and generic names can be different (medicines for other conditions, over-the-counter from country to country. Usually there is no major difference medicines, herbs, medicines from relatives, etc). Delivery Devices for Inhaled Medicines ✔ Call your health care provider promptly if you have any Bronchodilators and steroids are usually taken by inhaling serious side effects. These inhaled medicines have recently been Health Care Provider’s Contact Numbers/ developed in a dry powder form as well as liquid spray. The information appearing in this series is for educational purposes only and should not be used as a substitute for the medical advice one one’s personal health care provider. Elaine Turner Introduction Medications, both prescription and over-the-counter, are used every day to treat acute and chronic illness. Research and technology constantly improve the drugs we have available and introduce new ones. Although medicines are prescribed often, it is important to realize that they must still be used with caution. A food/drug interaction occurs when a food, or one of its components, interferes with the way a drug is used in the body. A drug/nutrient interaction occurs when a drug affects the use of a nutrient in the body. We hope this will help you see the potential for interactions and learn to avoid them. Be sure to talk with your doctor and pharmacist to get the maximum benefits from your medications. How Drugs React in the Body Risk Factors In order to understand food/drug and Risk for food/drug and drug/nutrient drug/nutrient interactions, it’s important to interactions can be affected by many factors understand how drugs work in the body. The drug is absorbed into the blood • body composition and transported to its site of action. The body responds to the drug and • number of medications used the drug performs a function. University Cooperative Extension Program, and Boards of County Commissioners Cooperating. Always check with your pharmacist about Effects of drug/nutrient and food/drug possible effects of alcohol on your interactions vary according to: medication. See Table 1 for specific examples of Nutritional status: nutrition-related health. Drug/Nutrient Interactions It is also possible for drugs to interfere with a person’s nutritional status. Other drugs affect the body’s use and/or Foods can interfere with the stages of drug excretion of nutrients, especially vitamins and action in a number of ways. If less of a nutrient is available to common effect is for foods to interfere with the body because of these effects, this may drug absorption. Second, nutrients or Sometimes drugs affect nutritional status by other chemicals in foods can affect how a increasing or decreasing appetite.
The role of calcium in peri- and postmenopausal membranes on protein catabolism in humans buy cheap premarin on line women's health issues in south africa. Factors associated mortality in elderly uraemic patients on chronic haemodi- with calcium absorption effciency in pre- and perimeno- alysis: a prospective 3-year follow-up study generic premarin 0.625mg otc womens health quizlet. Meta-analyses of ther- losses in patients treated with continuous ambulatory peri- apies for postmenopausal osteoporosis purchase premarin 0.625 mg line contemporary women's health issues for today and the future 5th edition. Severe dietary D supplementation to prevent fractures and bone loss in protein restriction in overt diabetic nephropathy: benefts people aged 50 years and older: a meta-analysis. Absorption of Association and a scientifc statement of the American calcium as the carbonate and citrate salts, with some obser- College of Cardiology Foundation and the American Heart vations on method. Fasting plasma glucose is a use- third National Health and Nutrition Examination Survey, ful test for the detection of gestational diabetes. Defnition and Diagnosis of Diabetes Mellitus review: The effect of vitamin D on falls: a systematic and Intermediate Hyperglycemia: report of a World review and meta-analysis. The vicious cycle of diabetes and better lower-extremity function in both active and inactive pregnancy. Artifcial sweeteners--do they Anencephaly before and after folic acid mandate--United bear a carcinogenic risk? Percentage of Vitamin A, Vitamin K, Arsenic, Boron, Chromium, carbohydrate and glycemic response to breakfast, lunch, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, and dinner in women with gestational diabetes. Breastfeeding and fatty acids and birth outcome: some frst results of the the basal insulin requirement in type 1 diabetic women. Longitudinal changes in selected physical systematic review of outcomes of maternal weight gain capabilities: muscle strength, fexibility and body size. Total energy expenditure in extruding memory T cells as a key feature of age-depen- the elderly. Grip strength changes over 27 yr in Estimating mortality risk in preoperative patients using Japanese-American men. Anorexia and weight loss between cutaneous cellular immune responsiveness and in the elderly. Causes range from loose dentures to debili- mortality in a nursing home population. Bacterial contamination weight on the risk of developing common chronic diseases of the small intestine is an important cause of occult mal- during a 10-year period. Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco body composition based on total-body nitrogen, potas- V. Failure to thrive, sacropenia panic white population: San Luis Valley Health and Aging and functional decline in the elderly. J Gerontol A Biol Sci Med risk screening characteristics of rural older persons: rela- Sci. Anorexia of aging: physiologic and patho- globin and several serum nutritional indicators. Reversal of protein-bound vitamin B12 malabsorp- of refned carbohydrates and the epidemic of type 2 diabe- tion with antibiotics in atrophic gastritis. Nutrition nutrient intakes are common and are associated with low factors in relation to cellular and regulatory immune vari- diet variety in rural, community-dwelling elderly. Do chemosensory changes infuence food intake University of California, Los Angeles. Nutrient intakes of senior women: balancing cholecalciferol absorption in the elderly and in younger the low-fat message. Calcium for prevention of fbers (dietary portfolio) on circulating sterol levels and osteoporotic fractures in postmenopausal women. Direct com- Effect of calcium and vitamin D supplementation on bone parison of a dietary portfolio of cholesterol-lowering foods density in men and women 65 years of age or older. Whole-grain intake age and Helicobacter pylori infection on gastric acid secre- and the risk of type 2 diabetes: a prospective study in men. Carbohydrates, dietary fber, and inci- hypochlorhydria causes high duodenal bacterial counts in dent type 2 diabetes in older women. Oral protein and energy undernourished elderly people: a prospective randomized supplementation in older people: a systematic review of community trial. Energy-dense plementation therapy in depleted patients with chronic meals improve energy intake in elderly residents in a nurs- obstructive pulmonary disease. Nutritional support and quality of life in stable 24-hour nutrient intakes in older adults. Lauque S, Arnaud-Battandier F, Mansourian R, et ment of foods for the elderly on nutritional status: food al. Protein-energy oral supplementation in malnourished intake, biochemical indices, and anthropometric measures. Providing nutrition supplements to institutionalized and nutritional status of elderly nursing home residents. J seniors with probable Alzheimer’s disease is least benef- Gerontol A Biol Sci Med Sci. Enteral (oral or tube administration) nutri- affected by dietary supplements but not by exercise. Improvements in nutritional bers’ preferences for nutrition interventions to improve intake and quality of life among frail homebound older nursing home residents’ oral food and fuid intake. Meal programs improve nutritional risk: a lon- hip fracture aftercare in older people. Changes containing nutritional supplements can affect usual energy in type of foodservice and dining room environment pref- intake postsupplementation in institutionalized seniors erentially beneft institutionalized seniors with low body with probable Alzheimer’s disease. The effect of oral health on diabetes-specifc formulas for patients with diabetes: a quality of life in an underprivileged homebound and non- systematic review and meta-analysis. Vitamins for chronic disease related quality of life of an elderly institutionalized popula- prevention in adults: scientifc review. Postprandial glycemia, glycemic index, Oral health, nutrient intake and dietary quality in the very and the prevention of type 2 diabetes. Food avoidance and expenditure and heart disease risk factors during weight food modifcation practices of older rural adults: associa- loss. Food-drug ciated with the coronary disease epidemic in Central and interactions: Careful drug selection and patient coun- Eastern Europe. Folate and vitamin B(6) intake and risk of acute myo- medication management for older adult clients. Association nisms relating to obesity, diabetes, and cardiovascular dis- between fsh consumption and all-cause and cause-specifc ease. The emphasis is on an integrated policy approach to investment and enterprise development. The term “country” as used in this study also refers, as appropriate, to territories or areas.